Lilly agrees to buy Orna Therapeutics for up to $2.4 billion

Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion in cash. Orna's lead asset, ORN-252, is a CD19-targeted in vivo CAR-T therapy built on circular RNA and lipid nanoparticles, aimed at B-cell-driven autoimmune diseases. The deal adds an in vivo cell therapy platform to Lilly's pipeline outside its metabolic franchise.

• Up to $2.4B in cash
• Split between upfront and milestone payments not disclosed
• Lead asset ORN-252 targets CD19 in B-cell autoimmune diseases